Hester Biosciences Limited has informed the Exchange regarding a press release dated May 09, 2025, titled "20250509 Q4 & FY25 Press Release".
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences reported its audited financial results for Q4 and FY25. On a standalone basis, total divisional product sales grew 12% for FY25 and 5% in Q4, driven by 16% growth in the Poultry Healthcare division and 6% growth in the Animal Healthcare division. Standalone PAT rose 17% for the full year and 30% in Q4, with EBITDA up 8% in both periods and EBITDA margin improving by 1 percentage point to 19%. On a consolidated basis, full-year PAT grew 36%, though Q4 consolidated PAT fell sharply by 76% and Q4 EBITDA margin compressed by 9 percentage points, weighed down by Hester Africa operations, though Africa's net loss narrowed to INR 102.69 million from INR 182.95 million. The board recommended a dividend of ₹7 per share (70%) for FY25 and statutory auditors issued an unmodified (clean) opinion on the results. Shah & Shah Associates was appointed as Secretarial Auditor for FY2025-26 to FY2029-30.
Positive for shareholders given steady growth in core divisions, healthy standalone margins, and a strong 70% dividend, though the sharp drop in consolidated Q4 PAT and margin compression at the Africa subsidiary may temper short-term sentiment. The clean audit opinion and clear growth pipeline (Avian Influenza vaccine launch, Africa expansion) support a constructive medium-term outlook.